Key statistics dashboard for Radiopharm Theranostics Limited (RADX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions.
Stock Data
| Price | $1.67 |
| Market Cap | $2M |
| Beta | 0.84 |
| Exchange | NASDAQ |
| Country | AU |
Valuation Multiples
| P/E Ratio | -0.51 |
| Price / Book | 1.14 |
| P/S | 6.84 |
| P/FCF | -0.83 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -39.41% |
| EBIT Margin | -2545.78% |
| EBITDA Margin | -2496.85% |
| Operating Margin | -2545.78% |
| Net Margin | -1992.46% |
Financial Health
| Current Ratio | 1.16 |
| Quick Ratio | 1.16 |
| Cash Ratio | 0.22 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | -626.93 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.76 |
Per-Share Data
| Revenue per share | 0.24 |
| Book Value per share | 1.90 |
| Cash per share | 0.35 |
| FCF per share | -1.93 |
| Tangible Book Value per share | 1.90 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Related companies: ADXN · BCLI · CDIO · CYCN · IBO · KTTA · MTNB
Explore sector: Healthcare · Biotechnology
More sections of RADX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks